Status:
UNKNOWN
Prediction of Liver-related Outcomes After HCV Cure
Lead Sponsor:
Hospital Universitario de Valme
Collaborating Sponsors:
Instituto de Salud Carlos III
Conditions:
Hepatitis C, Chronic
Sustained Virological Response
Eligibility:
All Genders
18+ years
Brief Summary
Objectives: To develop and validate a predictive model, applicable to daily practice, of liver complications emergence in hepatitis C virus (HCV)-infected patients and advanced fibrosis, who have achi...
Eligibility Criteria
Inclusion
- Had achieved SVR 12 weeks after DAA-based regimen, either with or without Peg-interferon
- Showed liver stiffness (LS) value ≥9.5 kPa prior to treatment
- Had LS measurement available at SVR time-point
Exclusion
- Individuals seropositive for HBsAg
- Individuals who refuse to participate
- Individuals under 18 years old
Key Trial Info
Start Date :
October 1 2011
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2021
Estimated Enrollment :
1035 Patients enrolled
Trial Details
Trial ID
NCT04460157
Start Date
October 1 2011
End Date
December 31 2021
Last Update
July 7 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital Universitario de Valme
Seville, Spain, 41014